Get the Stockscreener App
0.738
3.93%
+0.0279
After Hours:
.72
-0.018
-2.44%
Mira Pharmaceuticals Inc stock is currently priced at $0.738, with a 24-hour trading volume of 42,194.
It has seen a +3.93% increased in the last 24 hours and a -0.04% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.7234 pivot point. If it approaches the $0.7634 resistance level, significant changes may occur.
Previous Close:
$0.7101
Open:
$0.71
24h Volume:
42,194
Market Cap:
$10.91M
Revenue:
-
Net Income/Loss:
$-7.54M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-4.47M
1W Performance:
-2.89%
1M Performance:
-0.04%
6M Performance:
-51.45%
1Y Performance:
+0.00%
1D Range:
$0.71
$0.75
52W Range:
$0.6309
$6.48
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
737-289-0835
Address
855 North Wolfe Street, Suite 601, Baltimore
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Mira Pharmaceuticals reports 'positive' results from Ketamir-2 study - TipRanks.com - TipRanks
TipRanks
Who is Mira Murati, the creator of ChatGPT, and now OpenAI's interim CEO? | Today News - Mint
Mint
MIRA reports promising Ketamir-2 study, eyes FDA submission By Investing.com - Investing.com
Investing.com
Who is Mira Murati, the creator of ChatGPT, and now OpenAI's interim CEO? | Today News - Mint
Mint
Who is Mira Murati, the creator of ChatGPT, and now OpenAI's interim CEO? | Today News - Mint
Mint
Cannabis & psychedelics amendments in Congress (Newsletter: June 4, 2024) - Marijuana Moment
Marijuana Moment
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Mira Pharmaceuticals Inc (MIRA) Net Income 2024
MIRA net income (TTM) was -$7.54 million for the quarter ending September 30, 2023.
Mira Pharmaceuticals Inc (MIRA) Cash Flow 2024
MIRA recorded a free cash flow (TTM) of -$4.47 million for the quarter ending September 30, 2023.
Mira Pharmaceuticals Inc (MIRA) Earnings per Share 2024
MIRA earnings per share (TTM) was -$0.5283 for the quarter ending September 30, 2023.
About Mira Pharmaceuticals Inc
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
1.12%
0.04%
Cap:
|
Volume (24h):